IDXG: the cashflow

MyFinsight

For the quarter ending 2025-09-30, IDXG had $921K increase in cash & cash equivalents over the period. $1,821K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net income	911	1,007
Depreciation and amortization	111	196
Amortization of deferred financing fees	16	26
Stock-based compensation	7	24
Asset impairment - lab supplies	0	198
Credit loss expense	-	0
Change in fair value of note payable	-105	18
Amortization on operating lease right of use asset	100	193
Accounts receivable	-1,265	-1,313
Other current assets	-14	227
Interest accretion expense	-	0
Accounts payable	-8	-409
Accrued salaries and bonus	-601	-176
Other accrued expenses	16	-401
Operating lease liabilities	-98	-185
Bad debt expense reversal	-	0
Other long-term liabilities	100	214
Net cash provided by operating activities	1,938	1,755
Purchase of property and equipment	117	201
Net cash used in investing activities	-117	-201
Payments made on note payable	900	2,500
Series c conversion costs	0	13
Net cash used in financing activities	-900	-2,513
Net decrease in cash and cash equivalents	921	-959
Cash and cash equivalents at beginning of period	1,461	-
Cash and cash equivalents at end of period	1,423	-

Unit: Thousand (K) dollars